Denali Therapeutics (DNLI)

Denali Therapeutics (DNLI) Cash flow


Denali Therapeutics Cash Flow

DNLI's free cash flow for Q1 2023 was $-61.59M. For the 2023 fiscal year, DNLI's free cash flow was decreased by $-42.66M and operating cash flow was $-58.80M. See a summary of the company’s cash flow.
Cash Flow
Dec 22Dec 21Dec 20Dec 19Dec 18
Operating Cash Flow
$ -158.75M$ -244.72M$ -211.39M$ 416.15M$ -151.58M$ 50.12M
Investing Cash Flow
$ 11.34M$ -141.39M$ -21.63M$ -623.21M$ 147.71M$ -287.42M
Financing Cash Flow
$ 11.16M$ 310.67M$ 19.35M$ 634.75M$ 6.19M$ 97.02M
Cash Flow From Discontinued Operation
Other Cash Adjustment Inside Changein Cash
End Cash Position
$ 346.33M$ 219.56M$ 294.98M$ 508.64M$ 80.95M$ 78.62M
Income Tax Paid Supplemental Data
$ 4.00K$ 47.00K----
Interest Paid Supplemental Data
Issuance Of Capital Stock
-$ 296.21M$ 0.00$ 614.09M$ 0.00$ 94.41M
Issuance Of Debt
Repayment Of Debt
Free Cash Flow
$ -170.47M$ -262.55M$ -219.89M$ 413.06M$ -169.50M$ 46.72M
Domestic Sales
Foreign Sales
Currency in USD

Denali Therapeutics Cash Flow

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis